Download PDF
Exp Clin Endocrinol Diabetes 2015; 123(10): 632-636
DOI: 10.1055/s-0035-1555775
Article
© Georg Thieme Verlag KG Stuttgart · New York

Introducing Dendrosomal Nanocurcumin as a Compound Capable of in vitro Eliminating Undifferentiated Stem Cells in Cell Therapy Practices

M. A. Javidi
1   Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
,
F. Zolghadr
1   Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
,
S. Babashah
1   Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
,
M. Sadeghizadeh
1   Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
› Author Affiliations
Further Information

Publication History

Publication Date:
15 July 2015 (online)

Also available at
    Permissions and Reprints

Abstract

One of the major obstacles needed to be overcome before using cell therapy for clinical purposes is the high probability of tumor formation in patients who receive the transplants, as undifferentiated stem cells (SCs) have the potential to form teratomas/teratocarcinoma in xenotransplants. In this study the ability of dendrosomal nanocurcumin (solublized curcumin using a biodegradable non-toxic nano-carrier) to affect undifferentiated/hazardous cell, and hence increasing the safety of cell therapy (particularly in diabetes type I) by mesenchymal stem cells (MSCs) was examined. The results showed that after completion of differentiation of human mesenchymal stem cells (hMSCs) into insulin producing cells (IPCs), the expression level of insulin increases, although there remains a minority of undifferentiated cells which still express nestin (gene which is expressed in progenitor stem cells of IPCs). It indicates the emergence of a heterogeneous population containing undifferentiated and differentiated cells. Furthermore our data demonstrated that the expression level of p53 decreases during differentiation of hMSCs into IPCs which implies a more favorable microenvironment for tumor formation following the transplantation of such a heterogeneous population. After treatment with dendrosomal nanocurcumin, nestin expression eliminated, however no significant effect on the expression and secretion of insulin was observed. Together our data shows that dendrosomal nanocurcumin have the ability to affect residual undifferentiated stem cells after the completion of differentiation of MSCs induced to differentiate into IPCs; while it exerts no significant harmful effect on the survival and function of differentiated cells. With regard to the obtained results in this study, exploiting dendrosomal nanocurcumin, after completion of induced differentiation of stem cells and prior to the transplantation step, can be suggested as a very efficient, safe and cost-effective method to eliminate the residual undifferentiated stem cells in cell therapy practices in order to considerably decrease the risk of tumor development following transplantation.

Key words

stem cells - nanocurcumin - diabetes - cell therapy

Supplementary Material

 

  • References

  • 1 Langer R, Vacanti JP. Tissue engineering. Science 1993; 260: 920-926
    CrossrefPubMedGoogle Scholar
  • 2 Polak DJ. Regenerative medicine. Opportunities and challenges: a brief overview. J R Soc Interface 2010; 7 (Suppl. 06) S777-S781
    CrossrefPubMedGoogle Scholar
  • 3 Hentze H, Graichen R, Colman A. Cell therapy and the safety of embryonic stem cell-derived grafts. Trends in biotechnology 2007; 25: 24-32
    CrossrefPubMedGoogle Scholar
  • 4 Tan G, Elefanty AG, Stanley EG. beta-cell regeneration and differentiation: how close are we to the ‘holy grail’?. Journal of molecular endocrinology 2014; 53: R119-R129
    CrossrefPubMedGoogle Scholar
  • 5 Drukker M, Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends in biotechnology 2004; 22: 136-141
    CrossrefPubMedGoogle Scholar
  • 6 Buzzard JJ, Gough NM, Crook JM et al. Karyotype of human ES cells during extended culture. Nature biotechnology 2004; 22: 381-382 author reply 2
    CrossrefPubMedGoogle Scholar
  • 7 Maitra A, Arking DE, Shivapurkar N et al. Genomic alterations in cultured human embryonic stem cells. Nature genetics 2005; 37: 1099-1103
    CrossrefPubMedGoogle Scholar
  • 8 Rubio D, Garcia-Castro J, Martín MC et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035-3039
    PubMedGoogle Scholar
  • 9 Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011; 11: 268-277
    CrossrefPubMedGoogle Scholar
  • 10 Kooreman NG, Wu JC. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J R Soc Interface 2010; 7 (Suppl. 06) S753-S763
    CrossrefPubMedGoogle Scholar
  • 11 Lee AS, Tang C, Cao F et al. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 2009; 8: 2608-2612
    CrossrefPubMedGoogle Scholar
  • 12 Hentze H, Loong P, Tein S et al. Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies. Stem Cell Research 2009; 2: 198-210
    CrossrefPubMedGoogle Scholar
  • 13 Choo AB, Tan HL, Ang SN et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 2008; 26: 1454-1463
    CrossrefPubMedGoogle Scholar
  • 14 Wilken R, Veena MS, Wang MB et al. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 2011; 10: 12
    CrossrefPubMedGoogle Scholar
  • 15 Hatcher H, Planalp R, Cho J et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65: 1631-1652
    CrossrefPubMedGoogle Scholar
  • 16 Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 2010; 343: 489-499
    CrossrefPubMedGoogle Scholar
  • 17 Dhillon N, Aggarwal BB, Newman RA et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499
    CrossrefPubMedGoogle Scholar
  • 18 Babaei E, Sadeghizadeh M, Hassan ZM et al. Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo. Int Immunopharmacol 2012; 12: 226-234
    CrossrefPubMedGoogle Scholar
  • 19 Timper K, Seboek D, Eberhardt M et al. Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochemical and Biophysical Research Communications 2006; 341: 1135-1140
    CrossrefPubMedGoogle Scholar
  • 20 Pittenger MF. Mesenchymal stem cells from adult bone marrow. In: Prockop DJ, Phinney DG, Bunnell BA. (ed.). Mesenchymal Stem Cells: Methods and protocols. Humana Press; 2008. p 27-44
    CrossrefGoogle Scholar
  • 21 Zolghadr F, Sadeghizadeh M, Amirizadeh N et al. How benzene and its metabolites affect human marrow derived mesenchymal stem cells. Toxicol Lett 2012; 214: 145-153
    CrossrefPubMedGoogle Scholar
  • 22 Plumb JA. Cell Sensitivity Assays: The MTT Assay. Methods in Molecular Biology 2004; p 165-169
    PubMedGoogle Scholar
  • 23 Skelin M, Rupnik M, Cencic A. Pancreatic beta cell lines and their applications in diabetes mellitus research. ALTEX 2010; 27: 105-113
    PubMedGoogle Scholar
  • 24 Gubler U, Hoffman BJ. A simple and very efficient method for generating cDNA libraries. Gene 1983; 25: 263-269
    CrossrefPubMedGoogle Scholar
  • 25 Hung SC, Chen NJ, Hsieh SL et al. Isolation and characterization of size-sieved stem cells from human bone marrow. Stem Cells 2002; 20: 249-258
    CrossrefPubMedGoogle Scholar
  • 26 Reger RL, Tucker AH, Wolfe MR. Differentiation and characterization of human MSCs. Methods Mol Biol 2008; 449: 93-107
    PubMedGoogle Scholar
  • 27 Turnovcova K, Ruzickova K, Vanecek V et al. Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media. Cytotherapy 2009; 11: 874-785
    CrossrefPubMedGoogle Scholar
  • 28 Anzalone R, Lo Iacono M, Corrao S et al. New emerging potentials for human Wharton’s jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells and Development 2010; 19: 423-438
    CrossrefPubMedGoogle Scholar
  • 29 Anzalone R, Lo Iacono M, Loria T et al. Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev 2011; 7: 342-363
    CrossrefPubMedGoogle Scholar
  • 30 Molchadsky A, Shats I, Goldfinger N et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 2008; 3: e3707
    CrossrefPubMedGoogle Scholar
  • 31 Huang Y, Yu 1 P, Li 1 W et al. p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation. Oncogene 2013; 33: 3830-3838
    PubMedGoogle Scholar